Clinical Trial Update: Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating low-dose rifaximin for covert hepatic encephalopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Covert Hepatic Encephalopathy

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Covert Hepatic Encephalopathy | Phase 4 | Status: COMPLETED